Iovance Biotherapeutics: A High-Risk Cancer Stock with Potential to Skyrocket by 2036

Iovance Biotherapeutics is a high-risk cancer stock with potential for significant upside. The company developed Amtagvi, a cancer-fighting medicine approved for melanoma, which has shown decent commercial progress and momentum. Iovance is working on approvals in the European Union, UK, Australia, and Canada, as well as label expansions and clinical trials in other forms of cancer. However, the company faces significant challenges, including potential clinical and regulatory roadblocks, and investors must do their due diligence and be comfortable with the heightened risk and volatility before investing.